Survival

Aug 03, 2021

Marked Progress in AL Amyloidosis Survival: A 40-Year Longitudinal Natural History Study

The recent decades have ushered in considerable advancements in the diagnosis and treatment of systemic light chain (AL) amyloidosis. As disease outcomes improve,…

May 05, 2015

Natural History and Outcomes in Localised Immunoglobulin Light-Chain Amyloidosis: A Long-Term Observational Study

New, More Accessible Staging System Developed to Predict Survival for Patients With Light Chain Amyloidosis

A new staging system developed with a more accessible test to predict the chance of survival in patients living with light chain (AL) amyloidosis. Led by…

Doctors Making Progress in Treating Amyloidosis

How to Cope With and Survive a Terrible, Incurable, Fatal Disease

Subscribe to

Newsletter

Expert and Community Perspectives on Attruby®

In this special session, Dr. Barry Trachtenberg and members of the ATTR amyloidosis community came together to share medical insights and lived experiences related to Attruby™ (acoramidis). This expert-led discussion explores the clinical data, the patient perspective, and what lies ahead for those considering or currently taking Attruby.